Metraipolis › archive › dc_efe272946a7b

Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer — Europe PMC PMID:41097679

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41097679
DOI
10.3390/cancers17193151
License (as archived)
solo-consultazione
Archived
2026-11-09T17:41:00.617Z
SHA-256 of the archived text
0e9d555cde3187714b5cbdb8f0c802ff9602c755b6686e53e28df230fc64c699
Stable URL of this page
https://metraipolis.com/documento/dc_efe272946a7b

How to cite

Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer — Europe PMC PMID:41097679 — Europe PMC (en), https://europepmc.org/article/MED/41097679 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_efe272946a7b (Metraipolis archive dc_efe272946a7b, sha256 0e9d555cde3187714b5cbdb8f0c802ff9602c755b6686e53e28df230fc64c699)
BibTeX
@misc{dcefe272946a7b,
  title = {Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer — Europe PMC PMID:41097679},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41097679},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_efe272946a7b; sha256 0e9d555cde3187714b5cbdb8f0c802ff9602c755b6686e53e28df230fc64c699},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41097679. Agents can read the archived copy with the MCP tool read_document.